Mark S Gresnigt

Dr. Mark S Gresnigt

Adaptive Pathogenicity Strategies · Head Microbial Pathogenicity Mechanisms

Phone: +49 3641 532-1305 Fax: +49 3641 532-0810 Email: mark.gresnigt@leibniz-hki.de

Topics
Curriculum vitae

Professional Career

Since
05/2020
Junior Research Group Leader, Leibniz Institute of Natural Product Research and Infection Biology - Hans Knoell Institute, Adaptive Pathogenicity Strategies
05/2018-
05/2020
Alexander von Humboldt Foundation Postdoctoral Fellowship, Leibniz Institute of Natural Product Research and Infection Biology - Hans Knoell Institute, Dept. Microbial Pathogenicity Mechanisms
03/2018-04/2018 Language Course German, Dresden, Germany
08/2015-03/2018 Postdoctoral researcher, Radboud University Medical Center, Department of Internal medicine, Nijmegen Institute for Infectious Diseases. Project: The development of novel immunomodulatory strategies for disseminated fungal infections
10/2010-05/2015 Phd, Radboud University Nijmegen Medical center, department of internal medicine, Nijmegen, The Netherlands. Project: Pattern recognition and cytokine signalling pathways in the host defence against Aspergillus fumigatus
02/2008-08/2010 M.Sc. Medical Biology, Radboud University, Nijmegen, The Netherlands
07/2003-07/2007 B.Sc. Biology and Medical Laboratory Research, Saxion University of Applied Sciences, Enschede, The Netherlands

Awards · Appointments · Scientific Activities

2018 Humboldt Research Fellowship for Postdoctoral Researchers
2018 Golden pipette award by the Laboratory for Experimental Internal Medicine Radboud University Nijmegen Medical center
2016 3rd prize for best thesis by the Radboud institute for molecular life sciences (RIMLS)
2015 Prize for best PhD thesis by the Dutch society for Immunology (NVVI)
2015 Youth development Prize by the German speaking society for Mycology (DMykG)
2013 ALLFUN Investigators Award
Publications

Austermeier S, Kasper L, Westman J, Gresnigt MS (2020) I want to break free - macrophage strategies to recognize and kill Candida albicans, and fungal counter-strategies to escape. Curr Opin Microbiol 58, 15-23. Details PubMed

Kumamoto CA, Gresnigt MS, Hube B (2020) The gut, the bad and the harmless: Candida Albicans as a commensal and opportunistic pathogen in the intestine. Curr Opin Microbiol 56, 7-15. Details PubMed

Domínguez-Andrés J, Novakovic B, Li Y, Scicluna BP, Gresnigt MS, Arts RJW, Oosting M, Moorlag SJCFM, Groh LA, Zwaag J, Koch RM, Ter Horst R, Joosten LAB, Wijmenga C, Michelucci A, van der Poll T, Kox M, Pickkers P, Kumar V, Stunnenberg H, Netea MG (2019) The itaconate pathway is a central regulatory node linking innate immune tolerance and trained immunity. Cell Metab 29(1), 211-220.e5. Details PubMed Open Access PDF

Graf K, Last A, Gratz R, Allert S, Linde S, Westermann M, Gröger M, Mosig AS, Gresnigt MS, Hube B (2019) Keeping Candida commensal: How lactobacilli antagonize pathogenicity of Candida albicans in an in vitro gut model. Dis Model Mech 12(9), dmm039719. Details PubMed Open Access PDF

Grondman I, Arts RJW, Koch RM, Leijte GP, Gerretsen J, Bruse N, Kempkes RWM, Ter Horst R, Kox M, Pickkers P, Netea MG, Gresnigt MS (2019) Frontline science: Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst. J Leukoc Biol 106(1), 11-25. Details PubMed Open Access PDF

Jaeger M, Matzaraki V, Aguirre-Gamboa R, Gresnigt MS, Chu X, Johnson MD, Oosting M, Smeekens SP, Withoff S, Jonkers I, Perfect JR, van de Veerdonk FL, Kullberg BJ, Joosten LAB, Li Y, Wijmenga C, Netea MG, Kumar V (2019) A genome-wide functional genomics approach identifies susceptibility pathways to fungal bloodstream infection in humans. J Infect Dis 220(5), 862-872. Details PubMed Open Access PDF

Jaeger M, Pinelli M, Borghi M, Constantini C, Dindo M, van Emst L, Puccetti M, Pariano M, Ricaño-Ponce I, Büll C, Gresnigt MS, Wang X, Gutierrez Achury J, Jacobs CWM, Xu N, Oosting M, Arts P, Joosten LAB, van de Veerdonk FL, Veltman JA, Ten Oever J, Kullberg BJ, Feng M, Adema GJ, Wijmenga C, Kumar V, Sobel J, Gilissen C, Romani L, Netea MG (2019) A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. Sci Transl Med 11(496), eaar3558. Details PubMed PDF

Maurer M, Gresnigt MS, Last A, Wollny T, Berlinghof F, Pospich R, Cseresnyes Z, Medyukhina A, Graf K, Gröger M, Raasch M, Siwczak F, Nietzsche S, Jacobsen ID, Figge MT, Hube B, Huber O, Mosig AS (2019) A three-dimensional immunocompetent intestine-on-chip model as in vitro platform for functional and microbial interaction studies. Biomaterials 220, 119396. Details PubMed

Assendorp EL, Gresnigt MS, Sprenkeler EGG, Meis JF, Dors N, van der Linden JWM, Henriet SSV (2018) Adjunctive interferon-γ immunotherapy in a pediatric case of Aspergillus terreus infection. Eur J Clin Microbiol Infect Dis 37(10), 1915-1922. Details PubMed Open Access

Gresnigt MS, Cunha C, Jaeger M, Gonçalves SM, Malireddi RKS, Ammerdorffer A, Lubbers R, Oosting M, Rasid O, Jouvion G, Fitting C, Jong DJ, Lacerda JF, Campos A, Melchers WJG, Lagrou K, Maertens J, Kanneganti TD, Carvalho A, Ibrahim-Granet O, van de Veerdonk FL (2018) Genetic deficiency of NOD2 confers resistance to invasive aspergillosis. Nat Commun 9(1), 2636. Details PubMed Open Access PDF

Kasper L, König A, Koenig PA, Gresnigt MS, Westman J, Drummond RA, Lionakis MS, Groß O, Ruland J, Naglik JR, Hube B (2018) The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. Nat Commun 9(1), 4260. Details PubMed Open Access

Akoumianaki T, Kyrmizi I, Valsecchi I, Gresnigt MS, Samonis G, Drakos E, Boumpas D, Muszkieta L, Prevost MC, Kontoyiannis DP, Chavakis T, Netea MG, van de Veerdonk FL, Brakhage AA, El-Benna J, Beauvais A, Latge JP, Chamilos G (2016) Aspergillus cell wall melanin blocks LC3-associated phagocytosis to promote pathogenicity. Cell Host Microbe 19(1), 79-90. Details PubMed

Links